Lee J. Helman

Lee J. Helman

Auto-generated profile, based on publicly available information

Lee J. Helman

Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2023 in Journal of Clinical Oncology
Verified
Journal Article
Open access
JFJoseph A. Flores-Toro
Joseph A. Flores-Toro
SJSubhashini Jagu
Subhashini Jagu
GAGregory T. Armstrong
Gregory T. Armstrong
DADavid F. Arons
David F. Arons
GAGregory J. Aune
Gregory J. Aune
TYTorunn Yock
Torunn Yock
Data-driven basic, translational, and clinical research has resulted in improved outcomes for children, adolescents, and young adults (AYAs) with pediatric cancers. However, challenges in sharing data between institutions, particularly in research, prevent addressing substantial unmet needs in children and AYA patients diagnosed with certain pediatric cancers. Systematically collecting and sharing data from every child and AYA can enable greater understanding of pediatric cancers, improve survivorship, and accelerate development of new and more effective therapies. To accomplish this goal, the Childhood Cancer Data Initiative (CCDI) was launched in 2019 at the National Cancer Institute. CCDI is a collaborative community endeavor supported by a 10-year, $50-million (in US dollars) annual federal investment. CCDI aims to learn from every patient diagnosed with a pediatric cancer by designing and building a data ecosystem that facilitates data collection, sharing, and analysis for researchers, clinicians, and patients across the cancer community. For example, CCDI's Molecular Characterization Initiative provides comprehensive clinical molecular characterization for children and AYAs with newly diagnosed cancers. Through these efforts, the CCDI strives to provide clinical benefit to patients and improvements in diagnosis and care through data-focused research support and to build expandable, sustainable data resources and workflows to advance research well past the planned 10 years of the initiative. Importantly, if CCDI demonstrates the success of this model for pediatric cancers, similar approaches can be applied to adults, transforming both clinical research and treatment to improve outcomes for all patients with cancer.

27 October 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
JLJohn A. Ligon
John A. Ligon
RSRussell Taylor Sundby
Russell Taylor Sundby
MWMary F. Wedekind
Mary F. Wedekind
FAFernanda I. Arnaldez
Fernanda I. Arnaldez
Jaydira Del RiveroJaydira Del Rivero
Jaydira Del Rivero
JGJohn Glod
John Glod
Purpose: Succinate dehydrogenase (dSDH)-deficient tumors, including pheochromocytoma/paraganglioma, hereditary leiomyomatosis and renal cell cancer–associated renal cell carcinoma (HLRCC-RCC), and gastrointestinal stromal tumors (GIST) without KIT or platelet-derived growth factor receptor alpha mutations are often resistant to cytotoxic chemotherapy, radiotherapy, and many targeted therapies. We evaluated guadecitabine, a dinucleotide containing the DNA methyltransferase inhibitor decitabine, in these patient populations. Patients and Methods: Phase II study of guadecitabine (subcutaneously, 45 mg/m2/day for 5 consecutive days, planned 28-day cycle) to assess clinical activity (according to RECISTv.1.1) across three strata of patients with dSDH GIST, pheochromocytoma/paraganglioma, or HLRCC-RCC. A Simon optimal two-stage design (target response rate 30% rule out 5%) was used. Biologic correlates (methylation and metabolites) from peripheral blood mononuclear cells (PBMC), serum, and urine were analyzed. Results: Nine patients (7 with dSDH GIST, 1 each with paraganglioma and HLRCC-RCC, 6 females and 3 males, age range 18–57 years) were enrolled. Two patients developed treatment-limiting neutropenia. No partial or complete responses were observed (range 1–17 cycles of therapy). Biologic activity assessed as global demethylation in PBMCs was observed. No clear changes in metabolite concentrations were observed. Conclusions: Guadecitabine was tolerated in patients with dSDH tumors with manageable toxicity. Although 4 of 9 patients had prolonged stable disease, there were no objective responses. Thus, guadecitabine did not meet the target of 30% response rate across dSDH tumors at this dose, although signs of biologic activity were noted.

3 July 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
SASrivandana Akshintala
Srivandana Akshintala
RSRussell Taylor Sundby
Russell Taylor Sundby
DBDonna Bernstein
Donna Bernstein
JGJohn W. Glod
John W. Glod
RKRosandra N. Kaplan
Rosandra N. Kaplan
CHChristine Heske
Christine Heske
Purpose: Antibodies against insulin-like growth factor (IGF) type 1 receptor have shown meaningful but transient tumor responses in patients with rhabdomyosarcoma (RMS). The SRC family member YES has been shown to mediate IGF type 1 receptor (IGF-1R) antibody acquired resistance, and cotargeting IGF-1R and YES resulted in sustained responses in murine RMS models. We conducted a phase I trial of the anti–IGF-1R antibody ganitumab combined with dasatinib, a multi-kinase inhibitor targeting YES, in patients with RMS (NCT03041701). Patients and Methods: Patients with relapsed/refractory alveolar or embryonal RMS and measurable disease were eligible. All patients received ganitumab 18 mg/kg intravenously every 2 weeks. Dasatinib dose was 60 mg/m2/dose (max 100 mg) oral once daily [dose level (DL)1] or 60 mg/m2/dose (max 70 mg) twice daily (DL2). A 3+3 dose escalation design was used, and maximum tolerated dose (MTD) was determined on the basis of cycle 1 dose-limiting toxicities (DLT). Results: Thirteen eligible patients, median age 18 years (range 8–29) enrolled. Median number of prior systemic therapies was 3; all had received prior radiation. Of 11 toxicity-evaluable patients, 1/6 had a DLT at DL1 (diarrhea) and 2/5 had a DLT at DL2 (pneumonitis, hematuria) confirming DL1 as MTD. Of nine response-evaluable patients, one had a confirmed partial response for four cycles, and one had stable disease for six cycles. Genomic studies from cell-free DNA correlated with disease response. Conclusions: The combination of dasatinib 60 mg/m2/dose daily and ganitumab 18 mg/kg every 2 weeks was safe and tolerable. This combination had a disease control rate of 22% at 5 months.

2 January 2026 in Clinical Cancer Research
Verified
Journal Article
Closed access
KWKristin M. Wessel
Kristin M. Wessel
KJKatherine A. Janeway
Katherine A. Janeway
LDLara E. Davis
Lara E. Davis
NDNicole Drezner
Nicole Drezner
MDMartha Donoghue
Martha Donoghue
LHLee J. Helman
Lee J. Helman
Osteosarcoma is the most common primary malignant bone tumor in children and adolescents, with a peak incidence coinciding with the pubertal growth spurt. Metastatic disease occurs in approximately 10% to 20% of newly diagnosed patients, most commonly in the lung. Although 5-year overall survival (OS) for patients with localized disease at diagnosis is approximately 70% after standard upfront treatment of multi-agent chemotherapy and surgical resection, patients with metastatic or recurrent disease have a 5-year OS of approximately 30% in the pediatric age group. Currently, there is no standard treatment or FDA-approved therapy for relapsed and refractory osteosarcoma. Progress in identifying promising new treatments has been limited by its complex disease biology and rarity, as well as unique challenges of clinical trial design, including unreliability of objective response rate as a predictor of drug activity. Given these challenges and the unmet need for new therapies, the FDA Oncology Center of Excellence hosted an educational symposium, “Current Challenges in Clinical Trial Design for Relapsed and Refractory Osteosarcoma,” in May 2023. During this mini symposium, patient advocates, regulators from the FDA, and academic thought leaders in the field of pediatric sarcoma discussed challenges in clinical trial design and implementation. Achieving progress in relapsed and refractory osteosarcoma will require intentional collaboration among all stakeholders to identify trial designs that are acceptable to patients and will provide sufficient evidence of efficacy and safety to support a marketing application. Herein, we summarize the key points and future directions discussed at this meeting.


18 July 2023
Verified
Other
Open access
PDF file
SASrivandana Akshintala
Srivandana Akshintala
RSRussell Taylor Sundby
Russell Taylor Sundby
DBDonna Bernstein
Donna Bernstein
JGJohn W. Glod
John W. Glod
RKRosandra N. Kaplan
Rosandra N. Kaplan
CHChristine Heske
Christine Heske
Adverse events possibly, probably, or definitely related to ganitumab across all 28 cycles (maximum grade per patient)